F9O

(2R,3S)-2-[3-[4,5-bis(chloranyl)benzimidazol-1-yl]propyl]piperidin-3-ol

Created:	2020-04-20
Last modified:	2023-07-05

Find Related PDB Entry
1 entries where F9O is found as a standalone ligand

Find related ligands:

Similar Ligands (Stereospecific) Similar Ligands (including Stereoisomers) Similar Ligands (Quick Screen) Similar Ligands (Substructure Stereospecific) Similar Ligands (Substructure including Stereoisomers)

Chemical Details
Formal Charge	0
Atom Count	40
Chiral Atom Count	2
Bond Count	42
Aromatic Bond Count	10

2D diagram of F9O

Toggle Hydrogen Toggle Labels

Chemical Component Summary
Name	(2R,3S)-2-[3-[4,5-bis(chloranyl)benzimidazol-1-yl]propyl]piperidin-3-ol
Systematic Name (OpenEye OEToolkits)	(2~{R},3~{S})-2-[3-[4,5-bis(chloranyl)benzimidazol-1-yl]propyl]piperidin-3-ol
Formula	C₁₅ H₁₉ Cl₂ N₃ O
Molecular Weight	328.237
Type	NON-POLYMER

Chemical Descriptors
Type	Program	Version	Descriptor
SMILES	CACTVS	3.385	O[CH]1CCCN[CH]1CCCn2cnc3c(Cl)c(Cl)ccc23
SMILES	OpenEye OEToolkits	2.0.7	c1cc(c(c2c1n(cn2)CCCC3C(CCCN3)O)Cl)Cl
Canonical SMILES	CACTVS	3.385	O[C@H]1CCCN[C@@H]1CCCn2cnc3c(Cl)c(Cl)ccc23
Canonical SMILES	OpenEye OEToolkits	2.0.7	c1cc(c(c2c1n(cn2)CCC[C@@H]3[C@H](CCCN3)O)Cl)Cl
InChI	InChI	1.03	InChI=1S/C15H19Cl2N3O/c16-10-5-6-12-15(14(10)17)19-9-20(12)8-2-3-11-13(21)4-1-7-18-11/h5-6,9,11,13,18,21H,1-4,7-8H2/t11-,13+/m1/s1
InChIKey	InChI	1.03	VXCNMWNXDDMFSX-YPMHNXCESA-N

Drug Info: DrugBank

DrugBank data are sourced from datasets licensed under a Creative Common's Attribution-NonCommercial 4.0 International License

DrugBank ID	DB18017
Name	Bersiporocin
Groups	investigational
Synonyms	(2r,3s)-2-(3-(4,5-dichloro-1h-benzo(d)imidazol-1-yl)propyl)piperidin-3-ol Bersiporocin Bersiporocin hydrochloride 3-piperidinol, 2-(3-(4,5-dichloro-1h-benzimidazol-1-yl)propyl)-, (2r,3s)
CAS number	2241808-52-4

Related Resource References

Resource Name	Reference
PubChem	142411678
ChEMBL	CHEMBL4802138

RCSB PDB Core Operations are funded by the U.S. National Science Foundation (DBI-2321666), the US Department of Energy (DE-SC0019749), and the National Cancer Institute, National Institute of Allergy and Infectious Diseases, and National Institute of General Medical Sciences of the National Institutes of Health under grant R01GM157729.